Literature DB >> 8442665

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease.

D L Miller1, I A Papayannopoulos, J Styles, S A Bobin, Y Y Lin, K Biemann, K Iqbal.   

Abstract

The pathological findings of Alzheimer's disease include amyloid deposition in cerebral blood vessels and in senile plaques. Both deposits are known to include peptides that contain a common sequence. Both forms of amyloid were isolated and their peptide compositions were determined. The peptides were resolved by size-exclusion chromatography in 70% formic acid, and reverse-phase chromatography in 60% formic acid, 0-40% acetonitrile. Senile plaque amyloid cores contain about 25% protein, about 70% of which is composed of peptides containing the beta-amyloid sequence. Amino-terminal sequencing of the core amyloid peptides (CAPs) revealed extensive amino-terminal heterogeneity, with variable amounts of blocked amino termini. Matrix-assisted, laser-desorption-time-of-flight mass spectrometry of the CAP mixture revealed an array of peptides the molecular weights of which corresponded to peptides beginning with each of the first 11 amino acids of the beta-peptide sequence and ending with Ala-42 of that sequence. The carboxyl-terminal residues were identified by tandem mass spectrometry of chymotrypsin digests. CAP possessed a minor degree of carboxyl-terminal heterogeneity. Cerebrovascular amyloid peptides (CVAPs) possessed minor degrees of both amino- and carboxyl-terminal heterogeneity. The major CVAP commenced at Asp-1 and ended at Val-40. Minor components of CAP possessed masses of 8000-9000 Da and the same amino-terminal residues as the major components of CAP. They may be precursors to the smaller CAPs. The differences in amino termini and carboxyl termini of CAPs and CVAPs suggest that the two types of amyloid form by different pathways, on which they encounter different proteases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8442665     DOI: 10.1006/abbi.1993.1112

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  118 in total

Review 1.  Cellular mechanisms of γ-secretase substrate selection, processing and toxicity.

Authors:  Gael Barthet; Anastasios Georgakopoulos; Nikolaos K Robakis
Journal:  Prog Neurobiol       Date:  2012-05-20       Impact factor: 11.685

Review 2.  Clinical-pathologic correlations in vascular cognitive impairment and dementia.

Authors:  Margaret Flanagan; Eric B Larson; Caitlin S Latimer; Brenna Cholerton; Paul K Crane; Kathleen S Montine; Lon R White; C Dirk Keene; Thomas J Montine
Journal:  Biochim Biophys Acta       Date:  2015-08-28

3.  Proteome-wide identification of proteins and their modifications with decreased ambiguities and improved false discovery rates using unique sequence tags.

Authors:  Yufeng Shen; Nikola Tolić; Kim K Hixson; Samuel O Purvine; Ljiljana Pasa-Tolić; Wei-Jun Qian; Joshua N Adkins; Ronald J Moore; Richard D Smith
Journal:  Anal Chem       Date:  2008-02-14       Impact factor: 6.986

4.  The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity.

Authors:  Asad Jan; Ozgun Gokce; Ruth Luthi-Carter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-08-11       Impact factor: 5.157

5.  Microsecond molecular dynamics simulation of Aβ42 and identification of a novel dual inhibitor of Aβ42 aggregation and BACE1 activity.

Authors:  Yuan-yuan Wang; Li Li; Tian-tian Chen; Wu-yan Chen; Ye-chun Xu
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

6.  1α,25-Dihydroxyvitamin D3-liganded vitamin D receptor increases expression and transport activity of P-glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells.

Authors:  Matthew R Durk; Gary N Y Chan; Christopher R Campos; John C Peart; Edwin C Y Chow; Eason Lee; Ronald E Cannon; Reina Bendayan; David S Miller; K Sandy Pang
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

Review 7.  Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.

Authors:  Khalid Iqbal; M Omar Chohan; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

8.  A role for c-Jun N-terminal kinase 1 (JNK1), but not JNK2, in the beta-amyloid-mediated stabilization of protein p53 and induction of the apoptotic cascade in cultured cortical neurons.

Authors:  Marie P Fogarty; Eric J Downer; Veronica Campbell
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

Review 9.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

10.  Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.

Authors:  D M Mann; T Iwatsubo; Y Ihara; N J Cairns; P L Lantos; N Bogdanovic; L Lannfelt; B Winblad; M L Maat-Schieman; M N Rossor
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.